RBC Europe’s CASI Pharmaceuticals CASI Stock Holding History

RBC Europe’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,000	Closed	-$65K	–	1132
2017 Q4	$65K	Buy	+2,000	New	+$54.3K	0.01%	423

Other funds holding CASI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RBC Europe's CASI Position: Q1 2018 in Review

RBC Europe sold out of CASI Pharmaceuticals (CASI) in Q1 2018, closing a stake of 2,000 shares — an estimated $65K sold.

RBC Europe first reported a position in CASI in Q4 2017 and held it in 1 quarter. The position peaked at $65K in Q4 2017. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2018.

RBC Europe reported no remaining CASI Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
RBC Europe sold 2,000 CASI Pharmaceuticals shares in Q1 2018, an estimated $65K.
RBC Europe first reported a position in CASI Pharmaceuticals in Q4 2017 and held it in 1 quarter.
RBC Europe's CASI Pharmaceuticals position peaked at $65K in Q4 2017.
44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2018.

Based on RBC Europe's 13F filing for Q1 2018, filed 9 Nov 2023.